Prognostic value of cardiac magnetic resonance imaging for idiopathic pulmonary arterial hypertension before initiating intravenous prostacyclin therapy

Circulation Journal

Volumn 76, Issue 7, 2012, Pages 1737-1743

  Yamada, Yoshitake ^a   Okuda, Shigeo ^a   Kataoka, Masaharu ^a,b   Tanimoto, Akihiro ^a   Tamura, Yuichi ^a   Abe, Takayuki ^a   Okamura, Tomonori ^a   Fukuda, Keiichi ^a   Satoh, Toru ^b   Kuribayashi, Sachio ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYORIN UNIVERSITY   (Japan)

Author keywords

Clinical outcome; Idiopathic pulmonary arterial hypertension; Magnetic resonance imaging

Indexed keywords

ANTICOAGULANT AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; PROSTACYCLIN; SILDENAFIL;

ADULT; AGE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; COHORT ANALYSIS; DEATH; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART RIGHT VENTRICLE ENDDIASTOLIC VOLUME; HEART RIGHT VENTRICLE ENDSYSTOLIC VOLUME; HEART RIGHT VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; MALE; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SEX; URIC ACID BLOOD LEVEL; WALKING;

ADULT; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; EPOPROSTENOL; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPERTENSION, PULMONARY; JAPAN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; URIC ACID; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT; YOUNG ADULT;

EID: 84863213453     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1237     Document Type: Review

References (24)

1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619.
2. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917-1928.
3. Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J 2011; 75: 1801-1810.
4. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
5. Lang IM, Plank C, Sadushi-Kolici R, Jakowitsch J, Klepetko W, Maurer G. Imaging in pulmonary hypertension. JACC Cardiovasc Imaging 2010; 3: 1287-1295.
6. Marrone G, Mamone G, Luca A, Vitulo P, Bertani A, Pilato M, et al. The role of 1.5T cardiac MRI in the diagnosis, prognosis and management of pulmonary arterial hypertension. Int J Cardiovasc Imaging 2010; 26: 665-681.
7. Benza R, Biederman R, Murali S, Gupta H. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 52: 1683-1692.
8. Kang KW, Chang HJ, Kim YJ, Choi BW, Lee HS, Yang WI, et al. Cardiac magnetic resonance imaging-derived pulmonary artery distensibility index correlates with pulmonary artery stiffness and predicts functional capacity in patients with pulmonary arterial hypertension. Circ J 2011; 75: 2244-2251.
9. van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG, Spreeuwenberg MD, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007; 28: 1250-1257.
10. Gan CT, Lankhaar JW, Westerhof N, Marcus JT, Becker A, Twisk JW, et al. Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest 2007; 132: 1906-1912.
11. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43-S54.
12. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S55-S66.
13. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278.
14. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.
15. Nagaya N, Uematsu M, Satoh T, Kyotani S, Sakamaki F, Nakanishi N, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 487-492.
16. Satoh T, Saji T, Watanabe H, Ogawa S, Takehara K, Tanabe N, et al. A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension. Circ J 2011; 75: 677-682.
17. Swiston JR, Johnson SR, Granton JT. Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: A systematic review of the literature. Respir Med 2010; 104: 1588-1607.
18. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: 78S-92S.
19. McLure LE, Peacock AJ. Imaging of the heart in pulmonary hypertension. Int J Clin Pract Suppl 2007; 61(Suppl156): 15-26.
20. Gan CT, Holverda S, Marcus JT, Paulus WJ, Marques KM, Bronzwaer JG, et al. Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. Chest 2007; 132: 11-17.
21. Kovacs G, Reiter G, Reiter U, Rienmuller R, Peacock A, Olschewski H. The emerging role of magnetic resonance imaging in the diagnosis and management of pulmonary hypertension. Respiration 2008; 76: 458-470.
22. Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28: 1195-1203.
23. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
24. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39: 1214-1219.